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Abstract: The personalized medicine is a model of medicine based on inherent difference given by the 
genetic heritage that characterizes us, diversity that can affect also our response to administered therapy. 
Nowadays, the term “adverse drug reaction” is identified with any harmful effect involuntary resulting 
from the use of a medicinal product; pharmacogenomics, in this field, has the aim to improve the drug 
response and to reduce the adverse reaction. 
We analyzed all reports of adverse reaction collected in the Pharmacovigilance Centre database of an 
Italian University Hospital, at the Sant’Andrea Hospital Sapienza University of Rome, in a period of 
two years. Comparing the data result from our analysis with several studies found in literature, it is evi-
dent that adverse drug reactions represent an important problem in the management of a health care sys-
tem. However, the development of pharmacogenetics and pharmacogenomics, allowing a personalized 
treatment, can improve clinical practice. This study highlights the great potential of pharmacogenomics 
in reducing adverse reactions and suggests the need for further pharmacogenomic clinical trials to better 
personalize drug treatment and to refine the current pharmacovigilance strategies. 
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INTRODUCTION 
 The personalized medicine, emphasizing a clinical ap-
proach based on the uniqueness of each patient, has among 
its objectives to identify the preventive and/or therapeutic 
actions that best suits the needs of the single patient. It is 
known that a model of medicine aimed at the possibility of 
identifying the susceptibility of each person to possible dis-
eases, measuring the risk, customizing the therapy according 
to the patient's genetic constitution and affecting the appro-
priateness of the drug administered, reduces the occurrence 
of adverse reactions [1]. Basic prerequisite is the inherent 
difference given by the genetic heritage that characterizes us, 
diversity that can affect our response to administered ther-
apy, in particular to its effectiveness but also to the possible 
side effects According to the World Health Organization 
(WHO), an adverse drug reaction (ADR) is “a response to a 
drug which is noxious and unintended, and which occurs at 
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doses normally used in man for the prophylaxis, diagnosis, 
or therapy of disease, or for the modification of physiologi-
cal function.” (WHO Technical Report No 498-1972). This 
definition does not include therapeutic failures and events 
due to errors in drug administration and non-compliance. 
Recently, with the European Directive 2010/84/EU and with 
the EU Regulation 1235/2010, published in the European 
Official Journal L. 348 on 31 December 2010, a new defini-
tion was introduced in the EU, in conformity with the termi-
nology used by WHO but with important news. The term 
ADR (adverse drug reaction) is identified with any harmful 
effect involuntary resulting from the use of a medicinal 
product, in accordance with the instructions contained in the 
marketing authorization, to medication errors and also to 
uses not complying with the instructions contained in mar-
keting authorization (including overdose, misuse, abuse of 
the medicine). The current definition does not depend on the 
type of the drug’s usage and implies the need to report ad-
verse reactions resulting from medication error, abuse, mis-
use, off label use, overdose and occupational exposure. Ad-
verse reactions are a set of clinical manifestations due to 
unpredictable reactions of the organism. Despite the possibility 
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that other factors may influence the individual's response to 
drugs, such as the diet, the environment, the age and life-
style, the knowledge of the genetic characteristics of the per-
son can facilitate the administration of therapies in a more 
effective and safe manner. In particular, the pharmacogenet-
ics is interested in the individual response to drugs that a 
person may have, in terms of safety and efficacy properties. 
Its goal is to use the knowledge, methodology, and the gene 
to improve the administration of drugs under the double pro-
file of their appropriateness and their non-harmfulness. This 
can be achieved through the selection of a drug already mar-
keted or with the design of new targets stilled on the genetic 
characteristics of the patient but also on the variants of the 
same disease; or due to the prescription and the dosage cali-
brated on different metabolic properties related to the genetic 
constitution of the person. In fact, pharmacogenetics and 
pharmacogenomics, studying the relationship between the 
genotype, the level of expression of all genes in the genome 
and the phenotype, allowed discovering not only genetic 
variations related to some diseases but also various markers 
associated with an individual susceptibility to drug sensitiv-
ity and treatment [2]. 
 The debate on the ethical and scientific substantiation of 
personalized medicine is particularly heated because while 
providing the possibility of great innovation, enhancing the 
appearance of the centrality of the individual patient charac-
teristics, it requires considerable human and financial re-
sources [3]. Keeping it in view, it is necessary to avoid the 
risk that may compress the protection of other healthcare 
sectors, without there being a real return and a fair balance 
between the expected benefits and the resources used [4-6]. 
The aim of this study is to analyze the phenomenon of the 
adverse drug reactions in Italy, and in particular at the 
Sant’Andrea Hospital in Rome and how these can affect the 
quality of care provided, thereby assessing the prospects for 
the future. 
MATERIALS AND METHOD 
 The study was conducted in a hospital of 818 beds, with 
a total number of hospital admissions of around 160 000 per 
year, covering a population of more than 900 000 inhabitants 
in Rome, Italy. The study period was from 1 February 2014 
to 28 February 2016. We used data collected in the Pharma-
covigilance Centre database for hospital management located 
in the Department of Pharmacy and Clinical Pharmacology 
of the Sant’Andrea Hospital in Rome, an Italian University 
Hospital. All ADR reports in the database have been in-
cluded, with data from each department of the structure, ex-
cept Obstetrics. The reports were classified according to year 
and month in which the adverse reaction took place, drugs 
were used, therapeutic indication of the drug category and 
class of adverse event occurred. The drugs used were classi-
fied into pharmacological groups on the basis of the Interna-
tional Classification ATC (Anatomical Therapeutic Chemi-
cal classification system) controlled by the WHO. Adverse 
reactions have been labelled according to the World Health 
Organization - Adverse Reaction Terminology (WHO-ART) 
classification and divided into categories on the basis of the 
affected organs. 
Statistical Analysis 
 A descriptive statistical analysis of categorical variables 
with the description of the frequencies (in absolute terms and 
in percentage) was performed. To assess the presence of as-
sociations between categorical variables, the statistical Chi-
square test was executed, with analysis of the groups by 
year, type of adverse reaction and therapeutic indication. The 
level of statistical significance was set as 0.05. 
RESULTS 
 During our study period (February 2014 - February 
2016), a total of 274 reports of adverse drug reactions were 
collected: 121 in 2014, 122 in 2015 and 31 during the 
months of January and February 2016 (Fig. 1). 
 Considering the context in which the examining of the 
adverse reactions occurred, 201 (74.4%) of the reports took 
place during the treatment of a chronic disease, 44 (16.3%) 
in patients with an acute disease, 22 (8.1%) in the course of a 
prophylactic treatment and 3 (1.1%) during a diagnostic im-
aging procedure (Fig. 2). 
 The association between ADR reports and the therapeutic 
indication class was statistically significant (Chi-square 
92.16, and p < 0.001). The most relevant therapeutic indica-
tions were infectious diseases (32.5% of cases), neurological 
diseases (17.9% of cases), psychiatric diseases (10.9% of 
cases), neoplastic diseases (10.6% of cases) and immuno-
rheumatological diseases (10.2% of cases). These results 
 
 
Fig. (1). Number of ADR reports collected during the study period. For the year 2016 are shown only the data for the months of January and 
February. 
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coincide with those obtained by the association between 
ADRs and drug category of the administered drug. In par-
ticular, 36.5% of ADRs concern antineoplastic and immu-
nomodulating agents, 26.6% anti-infectives for systemic use, 
17.2% drugs for the treatment of diseases of the nervous 
system. 
 The analysis of the class of antineoplastic and immuno-
modulating agents showed that the subcategory of biological 
drugs is associated with ADR reports in 20.8% of cases, con-
sisting of a total of 57 reports, distributed according to the 
active principle and the disease is shown in Table 1. In the 
subcategory of biologics, a significant impact of ADR re-
ports was observed during therapy for neoplastic diseases (9 
cases), but also, of particular importance, for rheumatoid 
arthritis (10 cases) and multiple sclerosis (9 cases). 
 Regarding the association between the subcategory of 
biological drugs and the reported adverse reaction, it was 
noted that out of a total of 57 reports, 19 (32,75%) consisted 
of drug ineffectiveness, including in particular, all the 5 
cases of therapy with Ranibizumab for the treatment of 
macular degeneration. 
 An important association is observed between ADR re-
ports and biopharmaceuticals for therapy of neoplastic dis-
eases in general, but also particularly, for rheumatoid arthri-
tis (10 cases) and multiple sclerosis (9 cases). Ineffectiveness 
represented a common adverse effect, occurring in 55 cases 
(20%). The absolute frequencies of cases of ineffectiveness 
by the pharmacological group and the therapeutic indication 
are shown in Table 2. 
 Analyzing the specific therapeutic indication, it appears 
that from a total of 89 cases of ADRs associated with infec-
tious disease, 35 (39.3%) occurred during therapy for 
chronic HCV hepatitis; of 49 cases of neurological disease, 
34 (69.4%) took place in the course of treatment for multiple 
sclerosis; of 30 cases associated with psychiatric pathology, 
18 (60%) were of bipolar disorder (2 unspecified, 14 type I 
and 2 type II); of 28 cases related with immuno-
rheumatological disease, 11 (39.3%) occurred during therapy 
for rheumatoid arthritis. 
 In particular, the analysis of the involved drugs showed a 
high frequency of adverse reactions during antiviral therapy 
for HCV. The distribution of ADR reports for the drugs used 
for the treatment of HCV according to the period is shown in 
Table 3. 
 Among antivirals, the drug most associated with adverse 
reactions proved to be the Boceprevir (12 reports, all in 
2014), followed by Telaprevir (7 reports of which 6 in 2014 
and 1 in 2015). Moreover, the association between Bocepre-
vir and type of ADR showed 4 reports for skin rash and itch-
ing, 5 reports for alterations in laboratory parameters as hy-
pertriglyceridemia and hyperuricemia, 2 reports for ineffec-
tiveness. 
 Another relevant fact is the high frequency of ADRs as-
sociated with the drug Asenapine for which a total of 25 re-
ports were collected of which, 16 consisted of drug ineffec-
tiveness, 6 of dysesthesia, 2 of sedation and 1 of extrapyra-
midal disorder. In 62.5% of cases, Asenapine was adminis-
tered for the treatment of bipolar I disorder; in the remaining 
cases, Asenapine was administered for manic state, 
dysthymic disorder, cyclothymic disorder and depression. 
 With regard to the type of ADR reported, 26.6% involved 
a combination of adverse effects, 15.7% comprised altera-
tions in laboratory parameters, 13.5% included dermatologic 
adverse effects, 12.8% was drug ineffectiveness and 10.9% 
involved neurological adverse effects. 
 In addition, during the study period, three fatal cases 
were reported of which, two miscarriages were associated 
with administration of Fingolimod and a cardiac arrest due to 
the administration of the iodinated contrast Iopromide. 
 With regard to the drug Fingolimod, used for the treat-
ment of multiple sclerosis, it was observed that on a total of 
41 ADR signs associated with this disease, 19 were inter-
ested in precisely the drug Fingolimod with 13 reports of 
ineffectiveness and 2 miscarriages. The latter finding is con-
sistent with the literature data about the frequency of miscar-
riages during treatment with Fingolimod [7]. 
 
 
Fig. (2). Distribution of adverse drug reactions reports depending on the year and the context in which they occurred. 
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Table 1. Distribution of ADR reports according to the active principle and the disease. Out of a total of 57 reports, 21 were related 
to the treatment of a rheumatic disease, while 10 were associated with the treatment of a neurological disease. 
 Rheumatic Diseases 
Neurological 
Diseases 
Neoplastic 
Diseases 
Immunological 
Disorders IBD HCV AMD 
Compassionate 
Use 
Undefined 
Indication Total 
Abatacept 3        1 4 
Etanercept 2         2 
Adalimumab 6    2     8 
Alemtuzumab        1  1 
Certolizumab 1         1 
Denosumab   2       2 
Golimumab 3         3 
Infliximab 1         1 
Natalizumab  4        4 
Nivolumab   3       3 
Ranibizumab       5   5 
Rituximab   4       4 
Tocilizumab 3         3 
Immunoglobulins 2 1  3      6 
Interferons  5    5    10 
Total 21 10 9 3 2 5 5 1 1 57 
 
Table 2. The absolute frequencies of cases of ineffectiveness by the pharmacological group and the therapeutic indication. 
 Rheumatic Diseases 
Neurological 
Diseases 
Psychiatric 
Diseases 
Neoplastic  
Disorders IBD HCV AMD 
Hematological 
Diseases 
Undefined 
Indication Total 
Blood and blood 
forming organs        2 1 3 
Antiinfectives for 
systemic use      2    2 
Antineoplastic and 
immunomodulating 
agents 
12 13  1 2  5   33 
Nervous system  1 16       17 
Total 12 14 16 1 2 2 5 2 1 55 
 
Table 3. ADR reports during treatment for chronic hepatitis C. 
 2014 2015 2016 Total 
ADR reports during treatment for infectious diseases 55 30 4 89 
ADR reports during treatment for chronic hepatitis C 24 10 1 35 
 
DISCUSSION 
The Future: Pharmacovigilance, Pharmacogenetics and 
Pharmacogenomics  
 Pharmacovigilance, monitoring the safety of medicines, 
is the scientific activity relating to the detection, assessment, 
understanding and prevention of side effects and other prob-
lems related to drugs. The European Union (EU) has intro-
duced a rigorous system to evaluate the safety of a medicinal 
product after it has obtained the marketing authorization and 
to take appropriate action, where this is necessary to protect 
public health. The EU's system provides different activities, 
including the collection and analysis of data, evaluation of 
reports, studies and risk management. Reports of adverse 
Personalized Medicine and Adverse Drug Reactions Current Pharmaceutical Biotechnology, 2017, Vol. 18, No. 3    5 
reactions have increased dramatically in the last decade, 
thanks to new European legislation that includes reports on 
medication error, abuse, misuse, use outside the indications 
registered, overdose and occupational exposure. A good 
pharmacovigilance system collects information on the risks 
of medicinal products under the double and important aspect 
of the protection of the individual patient's health but also 
public health. 
 With the application of the new legislation mentioned 
above, also in Italy, direct reporting of suspected ADRs was 
introduced by the patient or by the health care worker, in-
cluding among others, both figures in the decision-making 
process. In fact, in Italy, thanks to an ever greater attention to 
the issue together with the new European regulations, there 
has been an increase in reports of ADRs: according to data 
AIFA, Italy ranks since 2010 above the standard of 300 re-
ports per million inhabitants, that is the Gold Standard ac-
cording to the World Health Organization, showing the effi-
ciency of the pharmacovigilance system [8]. However, the 
key objective has been achieved of promoting and protecting 
public health by reducing the number and severity of ADRs; 
a better use of medicines means not only to report but also to 
analyze and interpret data in order to understand the nature 
of the effects unwanted and, where possible, prevent them.  
 This fits well with the use of pharmacogenetics and 
pharmacogenomics, namely the study of the genes that de-
termine the response to drugs: receptors of drugs, enzymes 
responsible for the transport of drugs and enzymes responsi-
ble for the metabolism. These are two disciplines of pharma-
cology and, generally pharmacogenetics refers to effects 
involving a limited number of genes, often involving drug 
metabolism, while pharmacogenomics involves the study of 
complex multi-gene patterns within the genome [9]. In re-
alty, there is no agreement on the difference between the two 
and they are often used interchangeably. In fact, the term 
“pharmacogenetics” is that originally defined while the term 
“pharmacogenomics” is more recent, having been born after 
the success of the human genome project [10-12]. So, some 
Authors suggested that the difference is just that pharmaco-
genetics analyses a single gene whereas pharmacogenomics 
studies many genes or the entire genome [13]. However, the 
development of technologies applied to these sciences has 
made it possible to use them in clinical practice, more and 
more usefully. The goal of these new sciences is to better 
apply the knowledge of genome in medical practice, improv-
ing the treatment and the drug response. Nowadays, it is pos-
sible in several fields of application such as, first of all, for 
antineoplastic and immunomodulatory drugs [14-19]. 
 The analysis carried out at our University Hospital pro-
vides results that reflect both the Italian trend of the past 
years [20] and the European one: most reports concern, in 
fact, antineoplastic and immunomodulating, antimicrobics 
and the central nervous system drugs (according to the Inter-
national Classification ATC drug). The antineoplastic and 
immunomodulatory drugs are most frequently associated 
with adverse reactions (including an important and frequent 
reaction, the ineffectiveness) mainly for two reasons: the 
diseases for which they are prescribed, as they are chronic 
diseases often associated with different comorbidity, and the 
fact that these biological drugs belong to the category of 
medications which represent difficult therapeutic response 
[21-25]. 
 The data of our observation agree with this trend by high-
lighting the high frequency of ADR reports in combination 
with biologics in about half of the cases consisting of inef-
fectiveness of the drug. Particularly interesting is the evi-
dence of ineffectiveness in all cases in which the drug Ra-
nibizumab was used in the treatment of macular degenera-
tion. In fact, several authors [26] found that the gene may 
affect the development of this disease and the response to 
drug treatment; in particular, a recent study [27] has proven 
the association between polymorphisms of Complement Fac-
tor H (CFH) and the effectiveness of drug therapy, demon-
strating the great utility that the pharmacogenomics can have 
in clinical practice. 
 Furthermore, interesting is the observation of the high 
frequency of adverse reactions associated with therapy for 
the treatment of Hepatitis C (35 cases in total, including 24 
cases in 2014); the drugs most associated with adverse reac-
tions in our observation were the boceprevir and telaprevir, 
both reported in the year 2014. Several observational studies 
had already shown in the past the possibility of frequent ad-
verse events associated with the hiring of these two drugs, 
but one study in particular [28], published in February of 
2015 has been noted as most of the patients (95%) treated 
with these two drugs had suffered an adverse reaction and 
appeared as the most frequent adverse events being derma-
tological ones, according to the data obtained from our work. 
These results are consistent in showing how, in practice, 
Boceprevir and Telaprevir are associated with a high fre-
quency of adverse reactions [29-30]. The pharmacovigilance 
of our hospital, in this case, was efficient as shown in results 
from the net reduction (less than half) of adverse events due 
to HCV therapy from 2014 to 2015. This efficiency can still 
be improved by further studies as well as by the use of 
pharmacogenomics: for example, a recent study of May 2016 
[31] offered an analysis of data derived from the sequence of 
HCV showing the association between the subtypes of the 
virus and the resistance to the different drugs generally used 
in therapy; this work is a useful approach to the understand-
ing of the mutations at the base of mechanisms of resistance 
to the drug and can be useful to optimize the antiviral ther-
apy.  
 Another result of great importance derived from this 
study appears to be the high frequency of ADRs associated 
with the drug Asenapine, of which there are a total of 25 
reports, of which 16 consist of ineffectiveness. The Asenap-
ine is a second generation antipsychotic medication, recently 
introduced in Italy, which has an action multi-receptor with 
different levels of affinity for various receptors; these char-
acteristics are the basis of the several adverse effects [32], 
not present in the older generation antipsychotic drugs, and 
of the efficacy profile [33-35]. Most of the studies in the 
literature concern the evaluation of the effectiveness of the 
Asenapina compared to other antipsychotics or to placebo, 
but for the treatment of schizophrenia [36]; in such cases, 
however, better efficiency is not seen in the use of the 
Asenapine. Some authors in a study, aimed to evaluate the 
effectiveness of this drug in bipolar I disorder [37] as they 
felt the need for a longer observation time and further studies 
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to answer this question. Of particular importance, however, 
appears the fact that Asenapine is extensively metabolized 
from the isoform CYP1A2 of cytochrome P450 as well as 
direct glucuronidation from uridina difosfatoglucoroniltrans-
ferasis (UGT). It is well known that CYP1A2 polymor-
phisms affecting drug metabolism and various studies show 
the correlation between these polymorphisms and response 
to the therapy with Olanzapine [38]. Therefore, pharmacoge-
nomic studies on Asenapine would allow a better under-
standing of the high frequency of ineffectiveness of this drug 
optimizing therapy. 
CONCLUSION 
 Observing these data, probably similar to those of other 
Hospitals in different countries, the first reflection to make is 
that the ADRs represent an important chapter to be consid-
ered in the management of a health care system and for the 
increasing number of drugs introduced into clinical practice, 
both for the relevant cost in terms of mortality/morbidity and 
economically [39]. These costs are expected to rise consider-
ing the fact that more and more drugs are being placed in the 
market and more and more individuals are receiving multiple 
medications at once (polypharmacy). The second reflection 
is that ADRs represent real "drug-induced disease" that 
poses a problem of differential diagnosis as very challenging. 
 The first step for a correct management of the problem is 
to form an adequate pharmacovigilance system with the pur-
pose to promptly report all serious ADRs that may especially 
occur after the drug is placed in the market [40, 41]. 
 Nowadays, there are a lot of therapies for important dis-
eases such as infections, cardiovascular disease, cancer and 
mental disorders. However, drug therapy is often not cura-
tive and may also cause adverse effects. The tendency to 
create drugs for extended use and not for an individual has 
shown that the therapeutic response is closely inter-
individual. Any drug can be therapeutic for some individuals 
and ineffective for others as some individuals show adverse 
effects while others do not. Pharmacogenomics offers us a 
choice: to opt for approach "a single drug cures all" to that of 
"personalized medicine." In this perspective, the pharmaceu-
tical industry should incorporate pharmacogenomics into 
development phases of a drug, especially during clinical tri-
als Phase II. Identifying specific genetic profiles for patients 
may create the basis for the approval and marketing of a spe-
cific medicine for a population [42-45]. 
 This study suggests that this can be possible, highlighting 
the great potential of genetic tests in prevention to adverse 
reaction [46]. The great problem is the lack of big clinical 
trials. In fact, in many clinical trials, a large number of pa-
tients have been recruited for the purpose of solving the 
problem of the variability of response between patients. 
However, despite the inclusion of a large number of patients, 
currently the identification of rare ADR (less than 1 in 1000) 
is a big challenge. In fact, rare ADRs can be demonstrated 
only by observing large populations of patients exposed to 
the drug.  
 One solution is to carry out safety studies on the vast 
drug and heterogeneous populations prior to approval of the 
drug in the market. This, however, can significantly increase 
the time and cost of drug development, invariably delaying 
the availability of new medicines. An alternative solution 
would be the use of pharmacogenetics not only as a tool to 
develop new therapeutically useful molecules, but also to 
refine the current pharmacovigilance strategies. Pharmaco-
genomics could then effectively be added to existing systems 
that provide physicians with guidelines for a prescription as 
much as possible without risk for patients, thus making it 
more secure. 
 Finally, we would like to fully agree with the statement 
that “It would be painfully ironic if, in our pursuit of person-
alized medicine in the sense of medicine tailored to persons’ 
genomes, we inadvertently abandon our pursuit of personal-
ized medicine in the sense of medicine that shows respect for 
persons” [47]. Certainly, this needs reciprocal respect be-
tween patient and doctor, and PM will have to have a vision 
of the involvement of citizens as educated, engaged, re-
sourceful, and responsible partners rather than passive re-
cipients of health care [48]. Once again, the technological 
and socio-economic difficulties are proposed as critical to 
the development and success of PM. The institutional level 
will have to be careful and understand the importance of 
educating citizens in PM and to propose solutions to address 
such challenges. 
 Responsible innovation anticipates and evaluates the po-
tential implications and societal expectations of technology 
in ways that are democratic, equitable, and sustainable 
(European Commission, 2013) [1, 49-50]. 
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